Omeros Corp. (OMER)

19.63
0.42 2.09
NASDAQ : Health Technology
Prev Close 20.05
Open 20.05
Day Low/High 19.49 / 20.23
52 Wk Low/High 8.36 / 25.20
Volume 371.33K
Avg Volume 864.60K
Exchange NASDAQ
Shares Outstanding 48.29M
Market Cap 967.79M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin

Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd.

Interesting OMER Put And Call Options For July 20th

Investors in Omeros Corp saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Omeros Corporation Reports First Quarter 2018 Financial Results

Omeros Corporation Reports First Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include: 1Q 2018 total and OMIDRIA ® revenues were $1.

Omeros Corporation To Announce First Quarter 2018 Financial Results On May 10, 2018

Omeros Corporation To Announce First Quarter 2018 Financial Results On May 10, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018, on Thursday, May 10, 2018, after the market closes.

First Week Of June 15th Options Trading For Omeros (OMER)

Investors in Omeros Corp saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

Additional Clinical Studies Supporting The Benefits Of OMIDRIA® Presented At The American Society Of Cataract And Refractive Surgery And American Society Of Ophthalmic Administrators Annual Meeting

Additional Clinical Studies Supporting The Benefits Of OMIDRIA® Presented At The American Society Of Cataract And Refractive Surgery And American Society Of Ophthalmic Administrators Annual Meeting

Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.

2 Small Biotechs That Continue to Look Good

2 Small Biotechs That Continue to Look Good

Several biotech names held up well or even had solid advances during last week's broad market selloff.

2 Small Biotechs That Look Good

2 Small Biotechs That Look Good

Achaogen and Omeros both rose as the Dow was losing 724 points.

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.

Commit To Purchase Omeros Corp At $5, Earn 22% Using Options

Commit To Purchase Omeros Corp At $5, Earn 22% Using Options

Investors eyeing a purchase of Omeros Corp stock, but tentative about paying the going market price of $10.01/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2020 put at the $5 strike, which has a bid at the time of this writing of $1.10.

Omeros Corporation Reports Fourth Quarter And Year-End 2017 Financial Results

Omeros Corporation Reports Fourth Quarter And Year-End 2017 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

Omeros Corporation To Announce Fourth Quarter And Year-End 2017 Financial Results On March 1, 2018

Omeros Corporation To Announce Fourth Quarter And Year-End 2017 Financial Results On March 1, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market...

Omeros Reports Significant Improvement In Overall Survival Data In OMS721-Treated Patients With Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Reports Significant Improvement In Overall Survival Data In OMS721-Treated Patients With Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ: OMER) today announced new results from the company's ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA).

Omeros Stock Sees Short Interest Increase 17.3%

Omeros Stock Sees Short Interest Increase 17.3%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,216,726 share increase in total short interest for Omeros Corp , to 8,251,440, an increase of 17.30% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Omeros is Now Oversold (OMER)

Omeros is Now Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Omeros Becomes Oversold (OMER)

Omeros Becomes Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Wednesday Option Activity: OMER, GLNG, RCII

Notable Wednesday Option Activity: OMER, GLNG, RCII

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 7,003 contracts have traded so far, representing approximately 700,300 underlying shares. That amounts to about 132.3% of OMER's average daily trading volume over the past month of 529,270 shares.

Omeros Corporation Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

Omeros Corporation Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration (FDA) on Omeros' protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA...

First Week of OMER August 2018 Options Trading

First Week of OMER August 2018 Options Trading

Investors in Omeros Corp saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros Corporation Announces FDA Approval Of OMIDRIA® For Use In Pediatric Patients

Omeros Corporation Announces FDA Approval Of OMIDRIA® For Use In Pediatric Patients

Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

Noteworthy Friday Option Activity: OMER, WBC, XON

Noteworthy Friday Option Activity: OMER, WBC, XON

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Omeros Corp , where a total volume of 7,875 contracts has been traded thus far today, a contract volume which is representative of approximately 787,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.1% of OMER's average daily trading volume over the past month, of 1.0 million shares.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

Omeros Corporation Reports Third Quarter 2017 Financial Results

Omeros Corporation Reports Third Quarter 2017 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

Extended Improvement In OMS721-Treated Patients With IgA Nephropathy Presented At American Society Of Nephrology Annual Meeting

Extended Improvement In OMS721-Treated Patients With IgA Nephropathy Presented At American Society Of Nephrology Annual Meeting

Omeros Corporation (NASDAQ: OMER) today announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of...

Omeros Corporation To Announce Third Quarter 2017 Financial Results On November 9, 2017

Omeros Corporation To Announce Third Quarter 2017 Financial Results On November 9, 2017

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2017 financial results for the period ended September 30, 2017, on Thursday, November 9, 2017, after the market closes.

TheStreet Quant Rating: D- (Sell)